scholarly journals Tumor-targeting upconversion�nanoparticle-based unimolecular micelles for simultaneous chemotherapy, photodynamic therapy, and fluorescence imaging for neuroendocrine cancer therapy

2016 ◽  
Vol 4 ◽  
Author(s):  
Chen Guojun ◽  
Jaskula-Sztul Renata ◽  
Harrison April ◽  
Vokoun Corinne ◽  
Wang Liwei ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Therapy ◽  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Neuroendocrine Cancer

Double pH-sensitive Nanotheranostics of Polypeptide Nanoparticle-Encapsulated BODIPY with Both NIR Activated Fluorescence and Enhanced Photodynamic Therapy

2021 ◽  
Author(s):  
Huiping Dang ◽  
Quan Cheng ◽  
Youliang Tian ◽  
Changchang Teng ◽  
Kai Xie ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Fluorescence Imaging ◽  
Intelligent Systems ◽  
Ph Sensitive ◽  
Nir Fluorescence

To achieve accurate fluorescence imaging-guided cancer therapy, intelligent systems with specific responsiveness to the tumor microenvironment need to be designed. Here, we have achieved both enhanced NIR fluorescence and photodynamic...

A theranostic nanoplatform: magneto-gold@fluorescence polymer nanoparticles for tumor targeting T1&T2-MRI/CT/NIR fluorescence imaging and induction of genuine autophagy mediated chemotherapy

Nanoscale ◽  
2018 ◽  
Vol 10 (22) ◽  
pp. 10467-10478 ◽  
Author(s):  
Guannan Wang ◽  
Kun Qian ◽  
Xifan Mei
Keyword(s):  
Cancer Therapy ◽  
Contrast Agent ◽  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Polymer Nanoparticles ◽  
Nir Fluorescence ◽  
T2 Mri

Novel contrast agent were designed for in vivo T1&T2-MRI/CT/NIR fluorescence imaging and induction of genuine autophagy-mediated chemosensitization for cancer therapy.

Two- and three-photon excitable quaternized imidazo[1,2-a]pyridines as mitochondrial imaging and potent cancer therapy agents

2020 ◽  
Vol 18 (38) ◽  
pp. 7571-7576
Author(s):  
Eiji Hase ◽  
Hiroki Takanari ◽  
Keita Hoshi ◽  
Masaki Okamoto ◽  
Atsushi Tabata ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Therapy ◽  
Fluorescence Imaging ◽  
Imaging Agent ◽  
Targeted Photodynamic Therapy ◽  
Photon Fluorescence

We have synthesized four blue fluorescent imidazo[1,2-a]pyridines. One specific compound work as not only a two- and three-photon fluorescence imaging agent for the visualization of mitochondria, but also a potent mitochondria-targeted photodynamic therapy agent.

scholarly journals FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

RSC Advances ◽  
2017 ◽  
Vol 7 (59) ◽  
pp. 37369-37373 ◽  
Author(s):  
Pingping Liang ◽  
Jinjun Shao ◽  
Qianyun Tang ◽  
Weili Si ◽  
Qiang Wang ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Fluorescence Imaging ◽  
Tumor Targeting ◽  
Theranostic Agent ◽  
Imaging Properties

FDPP–HA was synthesized for tumor targeting photodynamic therapy. All experiments reveal that FDPP–HA presents excellent biocompatibility, high phototoxicity and specific targeted fluorescence imaging properties.

scholarly journals Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer

2022 ◽  
Author(s):  
Yvonne H. W. Derks ◽  
Sanne A. M. van Lith ◽  
Helene I. V. Amatdjais-Groenen ◽  
Lieke W. M. Wouters ◽  
Annemarie Kip ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Fluorescence Imaging ◽  
Multimodal Imaging ◽  
Tumor Targeting ◽  
First Generation ◽  
Solid Phase ◽  
Binding Motif ◽  
High Affinity ◽  
Biodistribution Studies

Abstract  Introduction The first generation ligands for prostate-specific membrane antigen (PSMA)–targeted radio- and fluorescence-guided surgery followed by adjuvant photodynamic therapy (PDT) have already shown the potential of this approach. Here, we developed three new photosensitizer-based dual-labeled PSMA ligands by crucial modification of existing PSMA ligand backbone structures (PSMA-1007/PSMA-617) for multimodal imaging and targeted PDT of PCa. Methods Various new PSMA ligands were synthesized using solid-phase chemistry and provided with a DOTA chelator for 111In labeling and the fluorophore/photosensitizer IRDye700DX. The performance of three new dual-labeled ligands was compared with a previously published first-generation ligand (PSMA-N064) and a control ligand with an incomplete PSMA-binding motif. PSMA specificity, affinity, and PDT efficacy of these ligands were determined in LS174T-PSMA cells and control LS174T wildtype cells. Tumor targeting properties were evaluated in BALB/c nude mice with subcutaneous LS174T-PSMA and LS174T wildtype tumors using µSPECT/CT imaging, fluorescence imaging, and biodistribution studies after dissection. Results In order to synthesize the new dual-labeled ligands, we modified the PSMA peptide linker by substitution of a glutamic acid into a lysine residue, providing a handle for conjugation of multiple functional moieties. Ligand optimization showed that the new backbone structure leads to high-affinity PSMA ligands (all IC50 < 50 nM). Moreover, ligand-mediated PDT led to a PSMA-specific decrease in cell viability in vitro (P < 0.001). Linker modification significantly improved tumor targeting compared to the previously developed PSMA-N064 ligand (≥ 20 ± 3%ID/g vs 14 ± 2%ID/g, P < 0.01) and enabled specific visualization of PMSA-positive tumors using both radionuclide and fluorescence imaging in mice. Conclusion The new high-affinity dual-labeled PSMA-targeting ligands with optimized backbone compositions showed increased tumor targeting and enabled multimodal image-guided PCa surgery combined with targeted photodynamic therapy.

Near‐Infrared‐II Nanomaterials for Fluorescence Imaging and Photodynamic Therapy

2021 ◽  
pp. 2002177
Author(s):  
Hongxin Lin ◽  
Zexi Lin ◽  
Konghua Zheng ◽  
Chenlu Wang ◽  
Lisheng Lin ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Fluorescence Imaging ◽  
Near Infrared

Lysosomal targeted NIR photosensitizer for photodynamic therapy and two-photon fluorescent imaging

2021 ◽  
Author(s):  
Ruiyuan Liu ◽  
Yuping Zhou ◽  
Di Zhang ◽  
Genghan He ◽  
Chuang Liu ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Fluorescence Imaging ◽  
Near Infrared ◽  
Fluorescent Imaging ◽  
High Fidelity ◽  
Design And Synthesis ◽  
Two Photon ◽  
Two Photon Fluorescence ◽  
Photon Fluorescence

Design and synthesis of near-infrared (NIR) emissive fluorophore for imaging of organelle and photodynamic therapy has received enormous attention. Hence, NIR emissive fluorophore of high-fidelity lysosome targeting, two-photon fluorescence imaging,...

scholarly journals Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tumors

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 428
Author(s):  
Emma Renard ◽  
Estel Collado Camps ◽  
Coline Canovas ◽  
Annemarie Kip ◽  
Martin Gotthardt ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Fluorescence Imaging ◽  
Ex Vivo ◽  
Growth Factor Receptor ◽  
Nuclear Imaging ◽  
A431 Cells ◽  
Site Specific ◽  
Variable Domains ◽  
Diagnostic Probe

Variable domains of heavy chain only antibodies (VHHs) are valuable agents for application in tumor theranostics upon conjugation to both a diagnostic probe and a therapeutic compound. Here, we optimized site-specific conjugation of the chelator DTPA and the photosensitizer IRDye700DX to anti-epidermal growth factor receptor (EGFR) VHH 7D12, for applications in nuclear imaging and photodynamic therapy. 7D12 was site-specifically equipped with bimodal probe DTPA-tetrazine-IRDye700DX using the dichlorotetrazine conjugation platform. Binding, internalization and light-induced toxicity of DTPA-IRDye700DX-7D12 were determined using EGFR-overexpressing A431 cells. Finally, ex vivo biodistribution of DTPA-IRDye700DX-7D12 in A431 tumor-bearing mice was performed, and tumor homing was visualized with SPECT and fluorescence imaging. DTPA-IRDye700DX-7D12 was retrieved with a protein recovery of 43%, and a degree of labeling of 0.56. Spectral properties of the IRDye700DX were retained upon conjugation. 111In-labeled DTPA-IRDye700DX-7D12 bound specifically to A431 cells, and they were effectively killed upon illumination. DTPA-IRDye700DX-7D12 homed to A431 xenografts in vivo, and this could be visualized with both SPECT and fluorescence imaging. In conclusion, the dichlorotetrazine platform offers a feasible method for site-specific dual-labeling of VHH 7D12, retaining binding affinity and therapeutic efficacy. The flexibility of the described approach makes it easy to vary the nature of the probes for other combinations of diagnostic and therapeutic compounds.

Sign in / Sign up

Export Citation Format

Share Document